Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry

详细信息    查看全文

• 作者：Zhili Zheng (1) <br> Nachimuthu Chinnasamy (1) <br> Richard A Morgan (1) <br>
• 刊名：Journal of Translational Medicine
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：10
• 期：1
• 全文大小：469KB
• 参考文献：1. Cooper LJ: Off-the-shelf T-cell therapy. / Blood 2010, 116:4741鈥?743. blood-2010-10-308379">CrossRef <br> 2. Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. / Proc Natl Acad Sci USA 1989, 86:10024鈥?0028. CrossRef <br> 3. Dotti G, Savoldo B, Brenner M: Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". / Hum Gene Ther 2009, 20:1229鈥?239. CrossRef <br> 4. Jena B, Dotti G, Cooper LJ: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. / Blood 2010, 116:1035鈥?044. blood-2010-01-043737">CrossRef <br> 5. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. / J Immunol 2009, 183:5563鈥?574. CrossRef <br> 6. Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA: Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. / J Clin Invest 2010, 120:3953鈥?968. CrossRef <br> 7. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. / Cancer Res 2010, 70:3027鈥?033. CrossRef <br> 8. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. / J Immunother 2009, 32:689鈥?02. b013e3181ac6138">CrossRef <br> 9. Nilson BH, Solomon A, Bjorck L, Akerstrom B: Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. / J Biol Chem 1992, 267:2234鈥?239. <br> 10. Bjorck L: Protein L. a novel bacterial cell wall protein with affinity for Ig L chains. / J Immunol 1988, 140:1194鈥?197. <br> 11. Nilson BH, Logdberg L, Kastern W, Bjorck L, Akerstrom B: Purification of antibodies using protein L-binding framework structures in the light chain variable domain. / J Immunol Methods 1993, 164:33鈥?0. CrossRef <br>
• 作者单位：Zhili Zheng (1) <br> Nachimuthu Chinnasamy (1) <br> Richard A Morgan (1) <br><br>1. Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA <br>

文摘

Background There has been significant progress in the last two decades on the design of chimeric antigen receptors (CAR) for adoptive immunotherapy targeting tumor-associated antigens. Structurally CARs consist of a single chain antibody fragment directed against a tumor-associated antigen fused to an extracellular spacer and transmembrane domain followed by T cell cytoplasmic signaling moieties. Currently several clinical trials are underway using gene modified peripheral blood lymphocytes (PBL) with CARs directed against a variety of tumor associated antigens. Despite the improvements in the design of CARs and expansion of the number of target antigens, there is no universal flow cytometric method available to detect the expression of CARs on the surface of transduced lymphocytes. Methods Currently anti-fragment antigen binding (Fab) conjugates are most widely used to determine the expression of CARs on gene-modified lymphocytes by flow cytometry. The limitations of these reagents are that many of them are not commercially available, generally they are polyclonal antibodies and often the results are inconsistent. In an effort to develop a simple universal flow cytometric method to detect the expression of CARs, we employed protein L to determine the expression of CARs on transduced lymphocytes. Protein L is an immunoglobulin (Ig)-binding protein that binds to the variable light chains (kappa chain) of Ig without interfering with antigen binding site. Protein L binds to most classes of Ig and also binds to single-chain antibody fragments (scFv) and Fab fragments. Results We used CARs derived from both human and murine antibodies to validate this novel protein L based flow cytometric method and the results correlated well with other established methods. Activated human PBLs were transduced with retroviral vectors expressing two human antibody based CARs (anti-EGFRvIII, and anti-VEGFR2), two murine antibody derived CARs (anti-CSPG4, and anti-CD19), and two humanized mouse antibody based CARs (anti-ERBB2, and anti-PSCA). Transduced cells were stained first with biotin labeled protein L followed by phycoerythrin (PE)-conjugated streptavidin (SA) and analyzed by flow cytometry. For comparison, cells were stained in parallel with biotin conjugated goat-anti-mouse Fab or CAR specific fusion proteins. Using protein L, all CAR transduced lymphocytes exhibited specific staining pattern ranging from 40 to 80% of positive cells (compared to untransduced cells) and staining was comparable to the pattern observed with anti-Fab antibodies. Conclusion Our data demonstrate the feasibility of employing Protein L as a general reagent for the detection of CAR expression on transduced lymphocytes by flow cytometry.